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Conclusion
Human monoclonal antibodies can be readily formulated using PCMC technology by 
incorporating precipitation stabilizing additives (PSA). PCMC coprecipitation leads to 
finely-divided dry powders, which can be rapidly reconstituted back into aqueous, to 
release the monoclonal antibody in monomeric form. Such PCMC mAb dry powders are 
attractive as a platform for alternate delivery applications.
Discussion
During the PCMC process, protein molecules are exposed to a very different 
environment to that arising during lyophilisation or spray-drying.  For molecules prone 
to self-association this can lead to a requirement for novel stabilising excipients. In this 
work we have demonstrated that a combination of glutamic acid and arginine are able 
to keep mAbs in a monomeric form during dehydration and precipitation using polar 
solvents. Lyoprotectants such as trehalose are much less effective. 
It is hypothesised that: 
• within solvent, protein association is predominately via charge-charge interactions
• neutral additives such as trehalose cannot prevent this
• Glu and Arg additives ion-pair with charged protein side-chains 
• a zwitterion-coating minimises intermolecular mAb association in dry-state
• additional neutral additives act synergistically by displacing water molecules
A combination of Glu and Arg has previously been reported to be useful for preventing 
protein precipitation in highly concentrated aqueous protein solutions with minimal 
reduction of specific protein-protein interactions (studied by NMR; Golovanov, A. et al., 
A Simple Method for Improving Protein Solubility and Long-Term Stability, JACS, 
2004, 8933-8939). This observation appears contradictory to the above hypothesis. 
However, this can be explained by the much weaker ion-pairing in water and the 
importance of hydrophobic interactions for driving protein association.  
These data demonstrate that the choice of best excipients for stabilisation of dry mAb
powders is a strong function of the dehydration pathway. The best excipients for 
preparation of PCMC are not predictable from lyophilisation or spray-drying results.
Bioactivity of PFCP
PCMC coprecipitation preserves the activity of the mAb. The bioactivity of the PFCP 
samples was tested in a PFCP specific ELISA. 
From the results it is clear that bioactivity has not been compromised by the PCMC 
coprecipitation process. Furthermore the protein loading measured is approximately 
equivalent to the theoretical composition, demonstrating that protein is not lost in the 
coprecipitation process, but is fully immobilized on the surface of the microcrystal. 
Sample Theoretical Protein Loading (%w/w)
Measured Protein 
Loading (%w/w) % Activity
PFCP1_56_1 16.8 15.6 92
PFCP1_56_2 17.2 16.8 95
PFCP1_56_3 32.7 30.0 108
PFCP1_56_4 32.7 28.5 109
PFCP1_56_5 26.6 26.1 107
PFCP1_56_6 26.6 23.4 96
Introduction
Protein Coated Micro Crystal (PCMC) technology was used to process a human 
therapeutic monoclonal antibody into dry powder formulations, which were studied 
under accelerated stress conditions. Changes in protein integrity on reconstitution 
were measured by size exclusion chromatography and turbidity measurements. The 
effect of  glutamic acid (Glu), L-arginine (Arg) and trehalose as precipitation stabilising 
additives was investigated.
PCMC Technology
PCMC are produced by coprecipitation of 
biomolecule and coprecipitant into GRAS 
solvent. The PCMC are formed by a rapid, 
self-assembly process, whereby the 
coprecipitant core (blue cubes) forms a 
support core and the biomolecule (yellow 
spheres) is immobilized on this crystal 
surface. 
solvent
coprecipitation
Abstract
Purpose. 
There is an increasing demand for differentiated strategies for formulating and delivering mAb in 
particulate form. The aim of this study was to investigate methods for optimising protein-coated 
microcrystal (PCMC) formulations of a human monoclonal antibody. PCMC technology provides a 
novel method of stabilising these important biopharmaceuticals in the form of dry powders 
Methods. 
Human monoclonal antibody coated microcrystals were prepared by coprecipitation of an 
aqueous mixture of histidine buffered human monoclonal antibody and concentrated glycine into 
propan-2-ol. The standard formulation contained mAb, buffer salts and glycine and the effect of 
including potential precipitation stabilizing additives (PSA) was investigated e.g. Glu, Arg. 
Following coprecipitation, the PCMC particles were filtered and air-dried to form free-flowing dry 
powders. Protein integrity was assessed by comparing optical clarity of the reconstituted 
formulations, protein concentration by UV spectroscopy and monomer content by size-exclusion 
chromatography, using a Tosoh TSKgel G3000 SWXL 7.8 mm ID x 30 cm column. 
Results. 
The measured protein loadings were found to be within 5% of the target protein loading for all 
formulations. However, the optical clarity of reconstituted PCMC prepared with optimal PSA was 
significantly better. Protein particulates could be observed in reconstituted standard samples, 
whilst PCMC utilising PSA, such as Glu, Arg, were optically clear and free of particulates. 
Consistent with this, measurement of the degree of monomer conservation following 
coprecipitation showed that material produced without PSA generally had monomer retention of 
less than 90% whilst optimised samples incorporating PSA resulted in >98% of monomer 
conservation. 
Conclusion. 
Human monoclonal antibodies can be readily formulated using PCMC technology by incorporating 
precipitation stabilizing additives (PSA). PCMC coprecipitation leads to finely-divided dry powders, 
which can be rapidly reconstituted back into aqueous, to release the monoclonal antibody in 
monomeric form.
Following coprecipitation, the suspension of PCMC particles was filtered and left to 
air dry overnight.
Human mAb PCMC Formulations
Monoclonal human antibody, PFCP, was 
obtained from Pfizer Inc, St Louis, MO. 
PFCP is a fully human monoclonal 
antibody specific for human cytotoxic T 
lymphocyte–associated antigen 4. 
PFCP PCMC were prepared by 
coprecipitation of an aqueous mixture of 
histidine buffered antibody and 
concentrated glycine coprecipitant into 
either propan-2-ol or 2-methyl-1-propanol.
PCMC were prepared in the presence and 
absence of the precipitation protective 
additive pair - Glu, Arg, and with and 
without trehalose.
aqueous mixture 
of concentrated 
coprecipitant and 
biomolecule
dropwise addition 
with stirring
water-miscible        
solvent
biomolecule-
coated      
microcrystals
The ratio of active mAb to coprecipitant/PSA was varied between 17%w/w and 
33 %w/w, as shown in this table (Theoretical Protein Loading (%w/w). 
Theoretical 
Protein Loading 
(%w/w)
Glycine 
(%w/w)
Precipitation 
Stabilizing 
Additive 
(%w/w)
Trehalose 
Dihydrate 
(%w/w)
mAb Stock (Stored 
@ 4-8ºC)
PFCP1_82_6 - No 
Additive IPA 41.1 57.0 0.0 0.0
PFCP1_82_1 - 
Trehalose Only IPA 32.0 44.4 0.0 22.0
PFCP1_56_1 IPA 16.8 55.7 4.5 22.3
PFCP1_56_2 IPA 17.2 56.9 13.7 11.4
PFCP1_56_3 IPA 32.7 46.4 19.4 0.0
PFCP1_56_4 2M1P 32.7 46.4 19.4 0.0
PFCP1_56_5 IPA 26.6 37.7 15.7 18.8
PFCP1_56_6 2M1P 26.6 37.7 15.7 18.8
Coprecipitation 
Solvent
PCMC Composition (%)
Sample
Stability Under Accelerated Stress Conditions
Monomer Content (%) Storage @ 40 oC for 47 weeks 
(Uncontrolled Humidity)
90
91
92
93
94
95
96
97
98
99
100
0.0 10.0 20.0 30.0 40.0 50.0
Time (Weeks)
M
o
n
o
m
e
r
 
C
o
n
t
e
n
t
 
(
%
)
PFCP1_56_2 PFCP1_56_3 PFCP1_56_4 PFCP1_56_5 PFCP1_56_6
Monomer Content (%) Storage @ 25oC for 13 weeks 
(Uncontrolled Humidity)
97.5
98
98.5
99
99.5
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Time (Weeks)
M
o
n
o
m
e
r
 
C
o
n
t
e
n
t
 
(
%
)
PFCP1_56_2 PFCP1_56_3 PFCP1_56_4 PFCP1_56_5 PFCP1_56_6
PFCP PCMC powders 
were stored at 25ºC in 
sealed vials at ambient 
humidity for a standard 
period of 13 weeks.
All samples retained 
>98.5% monomer 
content. 
(Liquid PFCP stored @ 2-8 
ºC had a monomer content of 
99.6% monomer.)
PFCP PCMC powders 
were stored in sealed 
vials at 40ºC ambient  
humidity for a standard 
period of ~47 weeks.
All samples retained 
≥95% monomer content. 
Sample PFCP1_56_6 
retained 98.5% monomer  
- a change of only 1.1% 
over 47 weeks.
(Liquid PFCP stored @ 2-8 
ºC had a monomer content of 
99.6% monomer.)
Dry PCMC mAb powders incorporating Glu and Arg exhibit high stability under 
accelerated stress conditions. Inclusion of a further neutral additive such as 
trehalose enhances stability even further.  
Monomer Content after Coprecipitation
After drying, the PFCP PCMC material was reconstituted into histidine buffer at a 
target protein concentration of 1 mg/mL, and monomer content was measured by 
size-exclusion chromatography, using a Tosoh TSKGel G3000 SWXL7.8 mm ID x 
30 cm column.
These results show that the mAb remains almost exclusively as monomer when 
PCMC coprecipitation is undertaken with Glu and Arg present. When no additives 
or trehalose alone were used, significant formation of higher molecular weight 
species occurred.
Monomer Content after Solvent Coprecipitation & Reconstitution  (%)
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